According to Piper Jaffray, Amylin AMLN price target is lowered to $17.
Piper Jaffray said that Amylin and Eli Lilly have terminated their partnership for exenatide with Amylin regaining worldwide rights, an unlikely result of ongoing litigation between the companies. “We are reducing our price target to $17 from $19, despite higher 2015 EPS, as we assume a higher discount rate for Amylin taking commercial responsibility.”
Amylin closed yesterday at $9.73
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in